Drug Profile
Iturelix
Alternative Names: Antide™; Nal-Lys-GnRH; ORF 23541Latest Information Update: 25 Jan 2005
Price :
$50
*
At a glance
- Originator Ortho-McNeil
- Developer Bayer Schering Pharma; Ortho-McNeil
- Class Antineoplastics; Contraceptives
- Mechanism of Action Gonadotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia; Cancer; Endometriosis; Female infertility; Prostate cancer; Uterine leiomyoma
Most Recent Events
- 01 Nov 2004 Discontinued - Phase-II for Female infertility in Europe (unspecified route)
- 01 Nov 2004 Discontinued - Preclinical for Benign prostatic hyperplasia in Switzerland (unspecified route)
- 01 Nov 2004 Discontinued - Preclinical for Endometriosis in Switzerland (unspecified route)